Invivyd, Inc.

Equities

IVVD

US00534A1025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.15 ^USD	+3.86%		-6.52%	-45.43%

Apr. 15	Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	CI
Apr. 12	Invivyd Names Jeremy Gowler as Interim CEO	MT

Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 07:16 am EDT

Invivyd, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 198.64 million compared to USD 241.32 million a year ago. Basic loss per share from continuing operations was USD 1.81 compared to USD 2.23 a year ago.

Latest news about Invivyd, Inc.

Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	Apr. 15	CI
Invivyd Names Jeremy Gowler as Interim CEO	Apr. 12	MT
Invivyd, Inc. Announces Executive Changes	Apr. 12	CI
Invivyd, Inc. Announces CEO Changes	Apr. 12	CI
North American Morning Briefing : Inflation Data, -2-	Apr. 08	DJ
Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9	Apr. 05	MT
Transcript : Invivyd, Inc. - Special Call	Apr. 04
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours	Apr. 04	MT
Invivyd Sees Covid-19 Prevention Treatment Revenue of Up to $200 Million This Year	Apr. 04	DJ
Invivyd, Inc. Provides Earnings Guidance for the Year 2024	Apr. 04	CI
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Mar. 26	MT
Invivyd Clears Significant Hurdle After Pemgarda Authorization, Morgan Stanley Says	Mar. 26	MT
Top Premarket Gainers	Mar. 26	MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	Mar. 26	MT
North American Morning Briefing : Tech in Focus on Reports of China Restrictions	Mar. 25	DJ
Invivyd Shares Give Back Some Gains After Surge From FDA Emergency Approval	Mar. 22	DJ
Transcript : Invivyd, Inc. - Special Call	Mar. 22
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt	Mar. 22	MT
Invivyd Gets FDA Emergency Use Approval to Prevent Covid-19 in Immunocompromised Adolescents, Adults	Mar. 22	DJ
Invivyd, Inc. Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial	Mar. 22	CI
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA? (Formerly VYD222) for Pre-exposure Prophylaxis of COVID-19	Mar. 22	CI
HC Wainwright Raises Price Target on Invivyd to $15 From $5, Keeps Buy Rating	Jan. 18	MT

Chart Invivyd, Inc.

Duration

Period

More charts

Company Profile

Invivyd, Inc. is a commercial-stage company, which is engaged in delivering antibody-based therapies. The Companyâs proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2 (COVID-19). Its PEMGARDA is the Companyâs first mAb in a planned series of innovative mAb candidates designed to keep pace with SARS-CoV-2 viral evolution. Its VYD2311 is optimized for neutralization potency against recent SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.15 USD

Average target price

9.375 USD

Spread / Average Target

+336.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INVIVYD, INC.	-45.43%	256M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs